301 results on '"Moorman, Nathaniel J."'
Search Results
2. A molecular mechanism for probabilistic bet hedging and its role in viral latency
3. Ribosomal protein RPL11 haploinsufficiency causes anemia in mice via activation of the RP-MDM2-p53 pathway
4. Caspase-7 activates ASM to repair gasdermin and perforin pores
5. Structure Activity of β‑Amidomethyl Vinyl Sulfones as Covalent Inhibitors of Chikungunya nsP2 Cysteine Protease with Antialphavirus Activity.
6. Chikungunya Virus RNA Secondary Structures Impact Defective Viral Genome Production.
7. Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.
8. Viral and host network analysis of the human cytomegalovirus transcriptome in latency.
9. FOXO transcription factors activate alternative major immediate early promoters to induce human cytomegalovirus reactivation
10. Engineering highly efficient backsplicing and translation of synthetic circRNAs
11. Structure Activity of β-Amidomethyl Vinyl Sulfones as Covalent Inhibitors of ChikungunyansP2 Cysteine Protease with Antialphavirus Activity
12. More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5‑a]pyrimidine Host CSNK2 Inhibitors for Combatting β‑Coronavirus Replication.
13. A 44-Nucleotide Region in the Chikungunya Virus 3′ UTR Dictates Viral Fitness in Disparate Host Cells.
14. Learning from history: do not flatten the curve of antiviral research!
15. Synthesis of 5-Benzylamino and 5-Alkylamino-Substituted Pyrimido[4,5-c]quinoline Derivatives as CSNK2A Inhibitors with Antiviral Activity
16. Specific RNA structures in the 5′ untranslated region of the human cytomegalovirus major immediate early transcript are critical for efficient virus replication
17. Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3
18. Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3
19. Alternative promoters drive human cytomegalovirus reactivation from latency
20. The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models
21. Optimization of 3-Cyano-7-cyclopropylamino-pyrazolo[1,5-a]pyrimidines toward the Development of an In Vivo Chemical Probe for CSNK2A
22. Human cytomegalovirus attenuates AKT activity by destabilizing insulin receptor substrate proteins
23. Precision mouse models with expanded tropism for human pathogens
24. An RNA structure-mediated, posttranscriptional model of human α-1-antitrypsin expression
25. Praemonitus praemunitus: can we forecast and prepare for future viral disease outbreaks?
26. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts
27. Data from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
28. Supplementary Data File 3 from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
29. Supplementary Data File 4 from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
30. Supplementary Data File 2 from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
31. Supplementary Data File 1 from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
32. Supplementary Data File 5 from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
33. Supplementary Data File 6 from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
34. Supplementary Data from GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
35. Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus Antivirals.
36. Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses
37. The Akt Forkhead Box O Transcription Factor Axis Regulates Human Cytomegalovirus Replication
38. Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice
39. Conserved coronavirus proteins as targets of broad-spectrum antivirals
40. Correction to “Mitochondrial Protease ClpP Is a Target for the Anticancer Compounds ONC201 and Related Analogues”
41. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis
42. Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β-Coronaviruses
43. Targeted Down Regulation Of Core Mitochondrial Genes During SARS-CoV-2 Infection
44. Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2
45. Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice
46. The Ends Dictate the Means: Promoter Switching in Herpesvirus Gene Expression
47. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis.
48. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
49. Two Genetic Differences between Closely Related Zika Virus Strains Determine Pathogenic Outcome in Mice
50. Comparative analysis of coronavirus genomic RNA structure reveals conservation in SARS-like coronaviruses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.